Evaluate Short-Term Outcomes of abciximab in ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Clinical Trials.

ABSTRACT:

Objectives

This meta-analysis was to verify the short-time efficacy and safety of abciximab in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI).

Background

Abciximab has long-term efficacy in patients with STEMI undergoing PCI, but the short-term efficacy is still controversial.

Methods

We conducted a systematic review and meta-analysis compared with or without abciximab in patients with STEMI undergoing PCI. The relevant randomized controlled trials were included by searching PubMed, EMBASE, Cochrane Library, and Web of Science databases and other sources. The relative risk (RR) and 95% confidence intervals (CI) of outcomes were calculated by the fixed-effects model.

Results

Ten randomized con

SUBMITTER: Bai N 

PROVIDER: S-EPMC9168187 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature